Print Page  Close Window


SEC Filings

S-1/A
OREXIGEN THERAPEUTICS, INC. filed this Form S-1/A on 04/09/2007
Entire Document
 
 

EXECUTION COPY
(3)   Performance of any part of this Agreement by a party is prevented or delayed by reason of Force Majeure and cannot be overcome by reasonable diligence to the satisfaction of either party;
 
(4)   The other party ceases, discontinues or indefinitely suspends its business activities related to the services to be provided under this Agreement, or the other party voluntarily or involuntarily files for bankruptcy; or
 
(5)   The party has given ninety (90) days written notice to the other party.
The party requesting termination will provide the other party with written notice specifying both the reason and the effective date of termination. Upon the giving of such notice of termination by either party, the UNIVERSITY will use its reasonable best efforts to limit or terminate any outstanding commitments.
Upon termination, UNIVERSITY shall deliver to SPONSOR in the state they exist as of the date of termination of all work product, and Confidential Information belonging to SPONSOR. SPONSOR shall within thirty (30) days after termination pay UNIVERSITY all payments due as of the effective date of termination.
The provisions of Articles V, VII, X, XI, XII, and XIV shall survive termination of this Agreement.
ARTICLE XIV – NOTICES
All notices or communications given hereunder shall be in writing and shall be delivered by hand, or by overnight courier, by facsimile with confirmation by mail, with all delivery charges prepaid and addressed to the parties as follows:
     
TO SPONSOR:
  Orexigen Therapeutics, Inc
 
  12481 High Bluff Drive
 
  San Diego, CA 92130
 
  Phone: (858) 480-2420
 
  Fax: (848) 480-2401
TO UNIVERSITY:
  Director, Technology & Research Collaborations
 
  Oregon Health & Science University, AD120
 
  2525 SW First Avenue, Suite 120
 
  Portland, OR 97201-4753
 
  Telephone: (503) 494-8200
 
  Fax: (503) 494-4729
 
   
 
  with copy to
 
   
TO PRINCIPAL INVESTIGATOR:
  Michael Cowley, Ph.D.

6